Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis

BACKGROUND Insulin-like growth factor-I (IGF-I) is a potent survival factor for motor neurons and is being investigated as possible therapeutic agent for amyotrophic lateral sclerosis. However, very little information is available on the components of the IGF-I system in this disease. Insulin-like growth factor binding proteins (IGFBPs) play an important part in regulating the bioavailability of IGF-I. METHODS We investigated the components of the IGF-I system in spinal cord sections of ten patients with amyotrophic lateral sclerosis and in ten controls without neurological disease. IGF-I was studied by western immunoblotting. IGFBPs and IGF-I receptors were investigated by immunohistochemistry and Western immunoblotting. FINDINGS Total IGF-I in ventral horn homogenates did not differ between patients and controls. However, free IGF-I was 53% lower in patients than in controls. Compared with controls, immunoreactivity in the spinal motor neurons of patients with amyotrophic lateral sclerosis was 64% higher for IGFBP2, 46% higher for IGFBP5, and 33% higher for IGFBP6, with upregulation of IGF-I receptors. Immunoreactivity for IGFBPs1, 3, and 4 did not differ between patients and controls. INTERPRETATION In the ventral horns of patients, free IGF-I is reduced, which could be because of specific increases in IGFBPs 2, 5, and 6 in spinal motor neurons. This abnormality might have an important role in the processes leading to motor neuron death, and should be taken into account when developing treatments aimed to stimulate IGF-I receptors in motor neurons.

[1]  Mulder Dw.  Clinical limits of amyotrophic lateral sclerosis. , 1982 .

[2]  M. Binoux,et al.  IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: its production is both IGF- and cell density-dependent. , 1997, The Journal of endocrinology.

[3]  Z. Molnár,et al.  Progressive Neuronal and Motor Dysfunction in Mice Overexpressing the Serine Protease Inhibitor Protease Nexin-1 in Postmitotic Neurons , 2001, The Journal of Neuroscience.

[4]  P. Leigh,et al.  A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.

[5]  J. Ma,et al.  The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies , 1995, Journal of the Neurological Sciences.

[6]  M. E. Lewis,et al.  Insulin-like Growth Factor-I: Potential for Treatment of Motor Neuronal Disorders , 1993, Experimental Neurology.

[7]  G. Braunstein,et al.  Serum insulin-like growth factor-I levels in amyotrophic lateral sclerosis. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[8]  M. Gaweł,et al.  Effect of recombinant human insulin-like growth factor-I on progression of ALS , 1997, Neurology.

[9]  R. Oppenheim,et al.  Effects of neurotrophic factors on motoneuron survival following axonal injury in newborn rats , 2000, Neuroreport.

[10]  W. Hong,et al.  Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors , 1993 .

[11]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[12]  P. Caroni,et al.  Mechanisms of insulin-like growth factor regulation of programmed cell death of developing avian motoneurons. , 1998, Journal of neurobiology.

[13]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[14]  W. Hong,et al.  Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells , 2000, Oncogene.

[15]  D. Troost,et al.  Insulin-like and fibroblast growth factors in spinal cords, nerve roots and skeletal muscle of human controls and patients with amyotrophic lateral sclerosis , 1994, Acta Neuropathologica.

[16]  N. Ling,et al.  Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Zimmer,et al.  A simple, versatile, sensitive and volume-independent method for quantitative protein determination which is independent of other external influences. , 1979, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[18]  S. Doré,et al.  Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. , 1996, Brain research. Molecular brain research.

[19]  T. Gustafsson,et al.  Different inhibitory actions of IGFBP-1, -2 and -4 on IGF-I effects in vascular smooth muscle cells. , 1999, The Journal of endocrinology.

[20]  V. Barrios,et al.  The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis , 1998, Neurology.

[21]  A. Hoeflich,et al.  Overexpression of Insulin-Like Growth Factor-Binding Protein-2 in Transgenic Mice Reduces Postnatal Body Weight Gain. , 1999, Endocrinology.

[22]  T. Hökfelt,et al.  Expression of insulin‐like growth factors and corresponding binding proteins (IGFBP 1–6) in rat spinal cord and peripheral nerve after axonal injuries , 1998, The Journal of comparative neurology.

[23]  M. Brooke,et al.  Advances in ALS Workshop Summary , 1996, Neurology.

[24]  D. Clemmons.  Insulin-like growth factor binding proteins and their role in controlling IGF actions. , 1997, Cytokine & growth factor reviews.

[25]  E. Denys,et al.  Somatomedin-C is not increased in the serum of patients with amyotrophic lateral sclerosis. , 1988, Muscle & nerve.

[26]  A. Taniguchi,et al.  Serpin=serine protease-like complexes within neurofilament conglomerates of motoneurons in amyotrophic lateral sclerosis , 1998, Journal of the Neurological Sciences.